

Sleep Disruption and Objective Sleepiness in Children With β -Thalassemia and Congenital Dyserythropoietic Anemia

Ariel Tarasiuk, PhD; Abdul-Hai Ali, PhD; Asher Moser, MD; Bruria Freidman, REEGT; Asher Tal, MD; Josef Kapelushnik, MD

Background: Sleep fragmentation and periodic leg movement syndrome (PLMS) have been reported in adults with iron deficiency anemia. Little is known about sleep function and daytime sleepiness in children with chronic anemia such as β -thalassemia or congenital dyserythropoietic anemia type 1 (CDA-1).

Objectives: To investigate if children and adolescents who have β -thalassemia (major or intermedia) or CDA-1 experience sleep fragmentation and objective daytime sleepiness and also to investigate if children and adolescents with β -thalassemia have obstructive sleep apnea.

Methods: Ten patients (7 males and 3 females) with β -thalassemia (mean [SD] age, 10.4 [7.3] years), 10 patients (7 males and 3 females) with CDA-1 (mean [SD] age, 13.5 [5.1] years), and 13 healthy volunteer control children (7 males and 6 females) (mean [SD] age, 10 [4] years) underwent nocturnal polysomnographic studies. A multiple sleep latency test was performed for 6 patients who had β -thalassemia and 8 patients who had CDA-1.

Results: Both patient groups, that is, those who had β -thalassemia and those who had CDA-1, had multiple arousals during sleep (mean [SD], 27.8 [11.4] events per

hour and 23.8 [11.8] events per hour, respectively) compared with the control subjects (12.1 [6.6] events per hour) ($P < .002$). Thirty-eight percent (10.6 events per hour) of the arousals in patients with β -thalassemia and 25% (6.0 events per hour) of the arousals in patients with CDA-1 were induced by periodic limb movements during sleep. In the control group, most (98%) arousals were spontaneous and unrelated to any definable event. The multiple sleep latency test average was 7.8 minutes for patients with β -thalassemia ($n=6$) and 10.7 minutes for patients with CDA-1 ($n=8$). Five patients with β -thalassemia and 4 patients with CDA-1 underwent a second polysomnographic study on the next night to confirm reproducibility. There was no significant change in the total number or index of arousals and no difference in the severity of the periodic limb movements during sleep compared with the results of the first polysomnographic study.

Conclusion: Children and adolescents with β -thalassemia or CDA-1 have evidence of impaired sleep function that is partially due to periodic limb movements during sleep and arousals that result in objective diurnal sleepiness.

Arch Pediatr Adolesc Med. 2003;157:463-468

From the Sleep-Wake Disorders Unit (Drs Tarasiuk, Ali, and Tal and Ms Freidman) and the Departments of Pediatric Hemato-Oncology (Drs Moser and Kapelushnik), Pediatrics-B (Dr Tal), and Physiology (Dr Tarasiuk), Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

β -THALASSEMIA IS a hereditary disease characterized in the major and intermediate types by severe and chronic hemolytic anemia resulting from mutations that affect the hemoglobin synthesis. Patients with β -thalassemia often have bone deformities, growth abnormalities, and hepatosplenomegaly. The resulting ineffective erythropoiesis causes osteoporosis and extreme expansion of marrow space in the skull, long bones, and facial bones.¹ Recently we described a child with β -thalassemia intermedia who developed an obstructive sleep apnea syndrome.² Computed tomographic scanning demonstrated obstruction of the nasopharynx resulting from extramedullary hematopoiesis.

Congenital dyserythropoietic anemia type 1 (CDA-1) is also a hereditary disorder affecting the normal differentiation-

proliferation pathway of the erythroid lineage. It constitutes an anemia of variable severity, hemolysis, jaundice, mild splenomegaly, and in some persons, iron overload related to repeated transfusions or ineffective erythropoiesis.³

To the best of our knowledge, there is no evidence on sleep architecture and diurnal functioning in children and adolescents who have iron deficiency anemia, β -thalassemia, or CDA-1. In adults, iron deficiency anemia has long been associated with many symptoms indicating poor sleep. Among the common findings in patients with iron deficiency anemia are insomnia, disturbed sleep, altered cognitive functions, and impairment of the quality of life.⁴⁻⁶ Repeated periodic limb movements during sleep (PLMS) have been described as being a common finding in patients with end-stage renal disease,

Table 1. Characteristics of 10 Patients With β -Thalassemia and 10 Patients With Congenital Dyserythropoietic Anemia Type 1 (CDA-1)

Patient No.	Type of β -Thalassemia	Hemoglobin Level, g/dL	Ferritin Level, ng/mL*	Spleen	Liver
Patients With β-Thalassemia					
1	Intermedia	8.4	475	-	-
2	Intermedia	8.1	98	-	-
3	Intermedia	8.9	53	+	+
4	Intermedia	7.2	67	-	-
5	Major	8.0	361	+	+
6	Major	10.9	458	-	-
7	Major	7.4	699	-	-
8	Major	6.9	896	-	-
9	Major	6.0	949	Spx	-
10	Major	8.0	80	+	-
Mean (SD)		8.0 (1.3)	414 (345)		
Patients With CDA-1					
1		10.9	166	-	-
2		10.5	200	-	-
3		10.0	305	-	-
4		8.9	339	-	-
5		8.9	227	+	-
6		11.2	224	-	-
7		9.6	288	-	-
8		8.2	1317	Spx	-
9		10.5	209	-	-
10		8.8	283	-	-
Mean (SD)		9.8 (1.0)	356 (342)		

Abbreviations: Spx, splenectomy; -, normal spleen or liver; +, enlarged spleen or liver.

To convert hemoglobin values to grams per deciliter multiple values by 0.6206.

*The normal range for ferritin is 16 to 300 ng/mL.

where anemia is a common feature.^{6,7} Treatment of iron deficiency anemia improves the quality of life and subjective sleep assessment^{5,8} as well as objective sleep assessment, that is, reduction in the number of arousals from sleep and in the sleep fragmentation indices while allowing more restorative sleep.^{6,9}

We investigated if children and adolescents who have β -thalassemia (major or intermedia) or CDA-1 have sleep fragmentation and objective daytime sleepiness. In addition, we investigated if children and adolescents with β -thalassemia have obstructive sleep apnea.

METHODS

STUDY POPULATION

Ten children and adolescents (7 male and 3 female patients; mean [SD] age, 10.4 [7.3] years) diagnosed as having β -thalassemia (major or intermedia) and 10 children and adolescents (7 male and 3 female patients; mean [SD] age, 13.5 [5.1] years) diagnosed as having CDA-1, all of Bedouin origin, were included in this study. **Table 1** summarizes the patient characteristics. The children and adolescents with β -thalassemia were unrelated. Most of the children and adolescents with CDA-1 were from one extended family. None of the children and adolescents had medical conditions that may disturb sleep such as trauma or depression. All were treated in the Pediatric Hematologic Unit, Soroka University Medical Center, Beer-

Sheva, Israel. Thirteen healthy volunteer children and adolescents (7 male and 6 female subjects; mean [SD] age, 10 [4] years) without a known history of anemia served as control subjects. The controls are not from the Bedouin population. All controls were examined by a pediatrician (A. Tal) and were found to be free of any medical illness. The protocol was approved by the Institutional Ethics Committee and informed consent was obtained from all guardians.

HEMATOLOGICAL EVALUATION

All patients with β -thalassemia or CDA-1 underwent blood testing during their routine monthly visits to the Pediatric Hematologic Unit. Clinical and laboratory evaluations of the patients with β -thalassemia were performed according to guidelines for clinical management of thalassemia.¹⁰ For this study, we used the hematological data that were obtained within 1 month of the sleep study.

POLYSOMNOGRAPHIC EVALUATION

Children and adolescents were encouraged to maintain their usual daily routine and medication regimen. They reported to the sleep laboratory at 8:30 PM and were discharged at 7 AM the next morning. A parent accompanied all children and adolescents for the duration of the sleep study. To compare reproducibility of sleep characteristics, 5 of the 10 patients with β -thalassemia and 4 of the 10 patients with CDA-1 agreed to participate in a second consecutive polysomnographic study conducted the next morning. None of the controls agreed to participate in a second polysomnographic study.

The polysomnographic study was performed as described previously¹¹: 2 silver-silver chloride cup electroencephalographic (EEG) electrodes filled with electrolyte were applied to the C3 and C4 locations and reference electrodes were attached behind the ears in the left (A1) and right (A2) mastoid areas. Two electromyographic electrodes were applied over the submental muscles. Two electrooculographic electrodes were applied 1 cm above the outer canthus of one eye and 1 cm below the outer canthus of the other eye. The montage arrangement for polysomnographic reading consisted of C3A2 and C4A1, and 2 electrooculographic recording electrocardiograms (1 from each eye).

Nasal airflow was monitored by a pressure transducer (Pro-Tech Service Inc, Woodinville, Wash), thoracic and abdominal movements were monitored by strain gauge electrodes, and hemoglobin oxygen saturation was monitored by pulse oximetry (model 4700; Ohmeda Inc, Louisville, Colo). Leg movements were measured using a mechanical strain gauge sensor (Scientific Laboratories Products Inc, Tel Aviv, Israel). The mechanical strain gauge sensor has been previously validated in our laboratory.¹¹

MULTIPLE SLEEP LATENCY TEST

Six of the patients with β -thalassemia and 8 of the patients with CDA-1 agreed to participate in the Multiple Sleep Latency Test (MSLT) on the morning after the first polysomnographic study. The MSLT was conducted beginning at 8 AM (2 hours after the final morning awakening), 10:30 AM, 1 PM, and 4 PM. The MSLT was performed for 20 minutes according to standard guidelines.¹¹⁻¹⁴ Parents were requested to stay in the room with their child to eliminate any external apprehension. The nap sleep latency was determined by the first occurrence of 3 consecutive epochs (90 seconds) of stage 1 sleep or the first epoch of any other stage of sleep.

SCORING

Sleep studies were interpreted according to recently published pediatric criteria.¹⁵ Nocturnal sleep-wake was scored in

accord with the Rechtschaffen and Kales criteria.¹⁶ Data were collected and streamed to an optical disk using a commercially available sleep monitoring system (model 4100; Sensor-Medics Inc, Yorba Linda, Calif). Signals were analyzed by computerized software and the results were edited by 2 of us (A. Tarasiuk and B. F.). Sleep latency was defined as time from lights out to the first occurrence of 3 consecutive epochs (90 seconds) of stage 1 sleep, or the first epoch (30 seconds) of any other stage of sleep. Rapid eye movement (REM) sleep latency was defined as the time from sleep onset to the first epoch of REM sleep. Sleep efficiency was calculated as the ratio of total sleep time to time in bed. The time spent in each sleep stage was expressed as the percentage of total sleep time.

Arousals and awakenings were scored according to the American Sleep Disorders Association's Sleep Disorders Atlas Task Force recommendation,¹⁷ modified for children.¹⁸ Arousals were defined by the presence of any of the following: (1) exceeding a 1.5-second period of α frequency EEG activity with augmentation of submental electromyographic signal; (2) presence of an EEG K-complex or desynchronization of EEG if clearly associated with leg movement or apnea; and (3) sleep stage shift if clearly associated with leg movement or apnea.¹⁹

Awakenings were defined as the presence of more than 15 seconds waking EEG following sleep onset with augmentation of the submental electromyographic signal. The arousal index and awakening index were calculated as the number of arousals or awakenings per hour of sleep. In addition, all arousals and awakenings were defined as one of the following: (1) associated with leg movement (jerks); an awakening or arousal was designated as associated with leg movement if a jerk signal preceded the EEG or submental electromyographic signal; (2) associated with obstructive apnea or obstructive hypopnea (see next paragraph); and (3) spontaneous leg movement (jerks). We did not score movements separately because in children most arousals and awakenings are associated with nonspecific movements.^{18,20} Determining the number of shifts to lighter sleep stages and frequency analysis of consecutive epochs were performed as the number of shifts from deeper to lighter non-REM sleep, or to wakefulness, or from REM sleep to any other stage or wakefulness, according to methods previously described.^{21,22}

Obstructive sleep apnea was defined as paradoxical breathing for at least 2 respiratory cycles with complete cessation of nasal airflow. Obstructive hypopnea was scored when the paradoxical breathing was accompanied by a reduction of at least 50% in airflow, resulting in either an arousal or in an arterial oxygen saturation (SaO₂) of at least 4%.^{15,18,20}

DATA ANALYSIS

Sleep study results of patients with β -thalassemia or CDA-1 were blindly analyzed. Data for all groups were compiled and tested for normal distribution (Kolmogorov-Smirnov test) and are presented as mean (SD). Data were compared using 1-way analysis of variance and 2-tailed *t* tests for nonpaired groups. The frequency analysis of consecutive epochs is presented as the median and analyzed using the Mann-Whitney test. To determine if there is a correlation between sleep variables and hematological laboratory test results (ie, hemoglobin and ferritin levels), a linear regression was performed. The null hypothesis was rejected at the 5% level.

RESULTS

HEMATOLOGICAL EVALUATION

Table 1 summarizes the patient characteristics and hematological findings of patients with β -thalassemia or

CDA-1. Patients with β -thalassemia were treated according to standard guidelines¹⁰; however, all were below the level of hemoglobin value suggested for β -thalassemia major. Mean hemoglobin concentration for patients with β -thalassemia was 8.0 (1.3) g/dL and for patients with CDA-1 9.8 (1.0) g/dL ($P < .004$). The apparent hemoglobin level reflects the patients' compliance with therapy. The ferritin concentration was 413.7 (344.9) ng/mL for patients with β -thalassemia and 355.8 (342.0) ng/mL for patients with CDA-1 ($P = .20$).

POLYSOMNOGRAPHY

Sleep Pattern

Table 2 summarizes the sleep characteristics. All children and adolescents spent about 6½ hours in bed. Total sleep time for patients with CDA-1 was 45 minutes shorter compared with the control group ($P < .01$) and sleep efficiency was reduced by 10% ($P = .04$). There were no significant differences in latency to sleep or in the cumulative percentage of any of the sleep stages. None of the patients with β -thalassemia or CDA-1 had sleep onset REM.

Sleep Fragmentation

The most striking sleep abnormality noted in both patient groups was severe sleep fragmentation. The patients with β -thalassemia had 27.8 (11.4) arousals and awakenings per hour of sleep (or events per hour); the patients with CDA-1 had 23.8 (11.8) events per hour compared with 12.1 (6.6) events per hour in the control group ($P < .002$). Furthermore, in 8 (80%) of the 10 patients with β -thalassemia and in 5 (50%) of the 10 patients with CDA-1, the arousals and awakenings index exceeded 20 events per hour. Only 2 (15%) of the 13 controls had an arousals and awakenings index exceeding 20 events per hour.

Patients with β -thalassemia had a PLMS index of 13.9 (12.1) events per hour (range, 9.3-36.1 events per hour) and 37.6% (5.1%) of the arousals were induced by PLMS. Comparatively, patients with CDA-1 had a PLMS index of 7.3 (11.1) events per hour (range, 0-51.1 events per hour) and 25.3% (27.8%) of the arousals were induced by PLMS. In the control group, 98% of the arousals and awakenings were spontaneous and were unrelated to any specific polysomnographic definable event. The percentage of arousals or awakenings associated with obstructive apneas or obstructive hypopneas was in the range of 0.8% to 1.0% for all groups.

Frequency analyses of consecutive sleep in stage 2, slow wave sleep, and REM were similar in the 3 groups. There were no significant differences in the number of shifts from deeper to lighter sleep stages between the controls (15.6 [5.0] events per study) and the patients with β -thalassemia or CDA-1 (16.2 [4.4] and 14.4 [5.3] events per study, respectively).

Respiratory Activity

There were no significant differences in respiratory disturbance index between the groups (Table 2). Wake SaO₂,

Table 2. Sleep Characteristics*

Variables	Control Subjects (n = 13)	Patients With β -Thalassemia (n = 10)	Patients With CDA-1 (n = 10)
Sleep pattern			
Total sleep time, min	370.0 (30.5)	362.8 (26.5)	314.9 (66.8)†
Sleep efficiency, %	89.6 (4.1)	84.0 (7.2)	79.6 (66.8)‡
Latency to sleep, min	32.5 (21.5)	32.4 (24.5)	43.0 (32.7)
Stage 1 sleep, %	1.8 (1.9)	3.3 (2.0)	2.8 (3.0)
Stage 2 sleep, %	58.0 (8.0)	61.8 (13.7)	56.1 (9.0)
SWS, %	21.2 (10.1)	18.6 (8.5)	26.3 (9.8)
REM, %	18.1 (6.9)	15.4 (7.0)	10.8 (7.4)
WASO, min	22.2 (16.0)	33.4 (23.7)	50.6 (50.2)
PLMS, events/h		13.9 (12.1)	7.3 (11.1)
MSLT, min§		7.8 (3.5) (n = 6)	10.7 (7.5) (n = 8)
Respiratory pattern			
RDI, events/h	1.1 (0.8)	0.5 (0.5)	1.3 (1.3)
REM RDI, events/h	2.9 (3.5)	2.0 (1.8)	3.5 (5.6)
T ₉₀ , %	0	0	0
Wake SaO ₂ , %	97.9 (1.2)	97.6 (2.8)	98.0 (0.8)
Nadir SaO ₂ , %	94.6 (1.5)	92.1 (4.5)	92.2 (4.5)

Abbreviations: CDA-1, congenital dyserythropoietic anemia type 1; DI, desaturation index; MSLT, multiple sleep latency test; PLMS, periodic limb movements syndrome; RDI, respiratory disturbance; REM, rapid eye movement; SaO₂, arterial oxygen saturation; SWS, slow wave sleep; T₉₀, the percentage of time with an oxygen saturation below 90%; WASO, wake after sleep onset.

*Data are given as mean (SD).

† $P < .01$, 1-way analysis of variance compared with control subjects.

‡ $P < .05$

§Values given for 6 patients with β -thalassemia and 8 patients with CDA-1.

Table 3. Reproducibility of the Polysomnographic Findings in Patients With Thalassemia and CDA-1*

Variable	Patients With β -Thalassemia (n = 5)		Patients With CDA-1 (n = 4)	
	First Night	Second Night	First Night	Second Night
TST, min	346 (14.1)	395.0 (51.8)	333.8 (61.2)	366.5 (30.0)
SEF, %	79.4 (5.9)	94.6 (2.7)†	83.5 (13.6)	92.5 (4.5)
Stage Sleep 2, %	51.6 (3.9)	49.9 (10.4)	55.1 (8.2)	59.2 (11.3)
SWS, %	19.4 (7.8)	25.3 (5.7)	26.6 (6.5)	17.8 (5.7)
REM, %	20.6 (6.0)	22.2 (8.2)	8.3 (3.7)	18.4 (5.4)‡
Ar and Aw index, events/h	28.2 (12.4)	24.1 (9.4)	18.8 (6.0)	17.1 (5.9)

Abbreviations: Ar and Aw, arousal and awakening; CDA-1, congenital dyserythropoietic anemia type 1; REM, rapid eye movement; SEF, sleep efficiency; SWS, slow wave sleep; TST, total sleep time.

*Data are given as mean (SD).

† $P < .01$, paired t test.

‡ $P < .05$.

mean SaO₂ during sleep, and nadir SaO₂ were in the normal range for all groups (Table 2). Thus, we did not find polysomnographic evidence to support a diagnosis of obstructive sleep apnea.

SECOND POLYSOMNOGRAPHIC STUDY

Reproducibility of the findings was confirmed in 9 patients. Five patients in the β -thalassemia group and 4 in the CDA-1 group consented to a second polysomnogram. This polysomnographic study was done on the next night (Table 3). Total sleep time did not significantly improve in the second polysomnographic study and sleep efficiency improved by 10% ($P < .01$). The improvement of sleep efficiency was caused by the combination of prolonged total sleep time and shorter sleep latency. There was neither change in the total number or index of awakenings and arousals nor a change in the PLMS index compared with the results of the first polysomnographic study.

SECOND MSLT RESULTS

Six patients with β -thalassemia and 8 patients with CDA-1 underwent an MSLT (Figure). The mean sleep latency on an MSLT was 7.8 (3.5) minutes for patients with β -thalassemia and 10.7 (7.5) minutes for patients with CDA-1. The evaluation of sleep latencies throughout the day is shown in the Figure. Both patient groups demonstrated an increase in sleep propensity throughout the day. We did not observe sleep-onset REM periods during MSLT in any patients.

COMMENT

This study provides objective evidence of sleep fragmentation in children and adolescents with 2 types of chronic anemia. The main polysomnographic manifestations were an increased arousal index and PLMS. These sleep abnormalities led to daytime hypersomnolence that was manifested by shortened MSLT

throughout the day. There was no evidence for obstructive sleep apnea in our study group. To our knowledge, the association between sleep function and β -thalassemia, or CDA-1, or both has not been reported in the literature. There is no evidence to support a genetic link between these 2 disorders and the sleep disruption we observed.


SLEEP FRAGMENTATION

Our finding of an arousal and awakening index in the controls was comparable to healthy individuals in the same age group. Healthy individuals in the age range of 15 to 30 years have an arousal index of 11 to 15 events per hour.¹⁹ Both groups of patients with anemia demonstrated frequent arousals and awakenings from sleep. We found an awakening and arousal index of 27.8 events per hour in our patients who had β -thalassemia and 23.8 events per hour in our patients who had CDA-1. Fifty percent to 80% of our patients had an arousal index above 20 events per hour. In adults, experimentally induced arousals at a rate of 20 events per hour led to impairment of daytime alertness.^{23,24} Considering these findings, we would expect to find excessive daytime sleepiness in our patients.

In adults, iron deficiency anemia can induce PLMS, which is associated with considerable sleep fragmentation. However, the severity of the observed PLMS in our patients was considerably lower than previously reported in adults^{6,9} and, therefore, may only partially explain the sleep disruption. Recently,²⁵ it was suggested that both iron deficiency and overload can cause motor impairment and cognitive deficits and that they may play a role in the pathophysiology of the restless leg syndrome. Iron overload is a feature of β -thalassemia and CDA-1. Finally, we found no evidence of obstructive sleep apnea. Thus, the sleep disturbances seen in this study are unrelated to obstructive respiratory events.

EXCESSIVE DAYTIME SLEEPINESS

Unlike adults in whom poor sleep may lead to excessive daytime sleepiness²⁶ and impairment of daily activities and mood,^{23,24,27} daytime sleepiness²⁸ in children is difficult to evaluate. The clinical signs of mild sleepiness (yawns, irritability, impaired concentration, momentary inattention, or lapses in performing a vigilance task) are similar to those of learning disabilities or behavior disorders in children and can often lead to misdiagnosis. In a previous study in children with juvenile rheumatoid arthritis,¹¹ the severe sleep fragmentation was associated with an afternoon nap, reflecting significant daytime somnolence.²⁹ Multiple sleep latency tests are probably the most reliable approach for evaluating daytime sleepiness.^{12,14} A limitation of our study is that MSLT data were not collected from our controls. We compared our data with available information for MSLT results in children. Palm et al¹² studied 18 healthy children between the ages of 8 and 12 years using polysomnography and MSLT. They reported that excessive daytime sleepiness, that is, an MSLT result of less than 20 minutes, is rarely seen in this age group. Furthermore, Randazzo et al,³⁰ using a nonstandard nap length of 30



Sleep latency test results using the Multiple Sleep Latency Test. Mean (SD) sleep latencies in 6 patients with β -thalassemia and 8 patients with congenital dyserythropoietic anemia type (CDA-1).

minutes, found an average sleep latency on MSLT of 23.5 minutes in 16 healthy children aged 10 to 14 years. Le-cendreux et al,¹³ using the 20-minute nap approach as in our study, found an average sleep latency on MSLT of 18.9 minutes in 21 controls. In a more recent study, Gozal et al,³¹ using a nonstandard nap length of 30 minutes, investigated 24 control patients between the ages of 4 and 7 years and found an average sleep latency on MSLT of about 24 minutes. Thus, it becomes apparent that an MSLT result of less than 10 minutes is exceedingly rare in healthy children and clearly differentiates sleepy from nonsleepy children. Gozal et al³¹ reported excessive daytime sleepiness as defined by an average sleep latency on MSLT of less than 10 minutes occurs in a small proportion of children with severe obstructive sleep apnea. Indeed, in children with juvenile rheumatoid arthritis, we reported an average sleep latency on MSLT of 10.3 minutes.¹¹ Our families of the children and adolescents with anemia that we studied, all of whom are Bedouins, did not report habitual afternoon naps. The Bedouin population, as whole, does not report habitual afternoon naps. In the current study we noted excessive daytime sleepiness and an average sleep latency on MSLT of 7.8 minutes in patients with β -thalassemia. The short time in bed is a relative limitation of the study since it may effect the MSLT result. However, since we noted considerable excessive daytime sleepiness in these patients, we assume that it may have little effect on MSLT results.

DATA REPRODUCIBILITY

In the current study, 9 of 20 children and adolescents performed 2 consecutive sleep studies, and data were comparable. The distribution of sleep stages was normal in both our patient and control groups. Reproducibility of our findings was established in a second polysomnographic test the next morning, in which sleep efficiency and latency to sleep improved, yet there was no change

What This Study Adds

To our knowledge, this study is among the first to characterize the sleep pattern and daytime sleepiness in children and adolescents who have β -thalassemia and CDA-1. In adults, iron deficiency anemia has been associated with impairment of sleep.

Children and adolescents who have chronic anemia have objective evidence of severe sleep abnormality. The results of this study indicated that there was a 2-fold increase in the number of arousals and awakenings for those who have anemia compared with healthy volunteer controls. This sleep disruption may result in excessive daytime sleepiness.

in the total number or index of awakenings and arousals. Our controls differed from both patient groups since they were not Bedouins, and this may represent a relative limitation of the study.

CONCLUSION

We found objective evidence of sleep dysfunction with excessive PLMS and arousals based on overnight polysomnographic test results, with a suggestion of excessive daytime sleepiness.

Accepted for publication November 25, 2002.

Corresponding author: Ariel Tarasiuk, PhD, Department of Physiology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, 84105 Israel (e-mail: arieltarasiuk@yahoo.com).

REFERENCES

1. Tunaci M, Tunaci A, Engin G, et al. Imaging features of thalassemia. *Eur Radiol*. 1999;9:1804-1809.
2. Kapelushnik J, Shalev H, Schulman H, Moser A, Tamary H. Upper airway obstruction-related sleep apnea in chilled with thalassemia intermedia. *J Pediatr Hematol Oncol*. 2001;23:525-526.
3. Tamary H, Shalmon L, Shalev H, et al. Localization of the gene for congenital dyserythropoietic anemia type I to a <1-cM interval on chromosome 15q15.1-15.3. *Am J Hum Genet*. 1998;62:1062-1069.
4. De Santo RM, Lucidi F, Violani C, Bertini M. Insomnia disassociated with systolic hypertension in uremic patients on hemodialysis. *Int J Artif Organs*. 2001;24:853-862.
5. Lee KA, Zaffke ME, Baratte-Beeb K. Restless legs syndrome and sleep disturbance during pregnancy: the role of folate and iron. *J Womens Health Gend Based Med*. 2001;10:335-341.
6. Benz RL, Pressman MR, Hovick ET, Peterson DD. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy

- on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (the SLEPO study). *Am J Kidney Dis*. 1999;34:1089-1095.
7. Winkelman JW, Chertow GM, Lazarus JM. Restless legs syndrome in end-stage renal disease. *Am J Kidney Dis*. 1996;28:372-378.
8. Paganini EP. In search of an optimal hematocrit level in dialysis patients: rehabilitation and quality-of-life implications. *Am J Kidney Dis*. 1994;24:S10-S16.
9. Sun ER, Chen CA, Ho G, Earley CJ, Allen RP. Iron and the restless legs syndrome. *Sleep*. 1998;21:371-377.
10. Vullo R, Modell B, Georganda E, in conjunction with Thalassemia Internationals Federation with the cooperation of the World Health Organization. *Guidelines for the Clinical Management of Thalassemia: Fighting for the Red in Blood*. New York, NY: Tenny Graphics Publisher; 2000.
11. Zamir G, Press J, Tal A, Tarasiuk A. Sleep fragmentation in children with juvenile rheumatoid arthritis. *J Rheumatol*. 1998;25:1191-1197.
12. Palm L, Persson E, Elmqvist D, Blennow G. Sleep and wakefulness in normal preadolescent children. *Sleep*. 1989;12:299-308.
13. Lecendreux M, Konofal E, Bouvard M, Falissard B, Mouren-Simeoni MC. Sleep and alertness in children with ADHD. *J Child Psychol Psychiatry*. 2000;41:803-812.
14. Carskadon MA, Dement WC, Mitler MM, Roth T, Westbrook PR, Keenan S. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. *Sleep*. 1986;9:519-524.
15. American Thoracic Society. Standards and indications for cardiopulmonary studies in children. *Am J Respir Crit Care Med*. 1996;153:866-878.
16. Rechtschaffen A, Kales A. *A Manual of Standardized Terminology: Techniques and Scoring System for Sleep Stage of Human Subjects*. US Public Health Service, 19.
17. American Sleep Disorders Association. EEG arousals: scoring rules and examples: a preliminary report from the Sleep Disorders Atlas Task Force for the American Sleep Disorders Association. *Sleep*. 1992;15:173-184.
18. Mograss MA, Ducharme FM, Brouillette RT. Movement/arousals: description, classification, and relationship to sleep apnea in children. *Am J Respir Crit Care Med*. 1994;150:1690-1696.
19. Mathur R, Douglas NJ. Frequency of EEG arousals from nocturnal sleep in normal subjects. *Sleep*. 1995;18:330-333.
20. Morielli A, Ladan S, Ducharme FM, Brouillette RT. Can sleep and wakefulness be distinguished in children by cardiorespiratory and videotape record? *Chest*. 1996;109:680-687.
21. Rothenberg SA. Measurements of sleep fragmentation. In: *Sleep Related Disorders in Internal Diseases*. New York, NY: Springer Publishing Co Inc; 1984:63-74.
22. Greenberg HE, Ney G, Scharf SM, Ravdin L, Hilton E. Sleep quality in Lyme disease. *Sleep*. 1995;18:912-16.
23. Stepanski E, Lamphere J, Badia P, Zorick F, Roth T. Sleep fragmentation and daytime sleepiness. *Sleep*. 1984;7:18-26.
24. Stepanski E, Lamphere J, Roehrs T, Zorick F, Roth T. Experimental sleep fragmentation in normal subjects. *Int J Neurosci*. 1987;33:207-214.
25. Krieger J, Schroeder C. Iron, brain and restless legs syndrome. *Sleep Med Rev*. 2001;5:277-286.
26. Levine B, Roehrs T, Stepanski E, Zorick F, Roth T. Fragmenting sleep diminishes its recuperative value. *Sleep*. 1987;10:590-599.
27. Saska P, Moldofsky H, Lue FA. Periodic movements in sleep and sleep-wake complaints. *Sleep*. 1985;8:319-324.
28. Moldofsky H. Evaluation of daytime sleepiness. *Clin Chest Med*. 1992;13:417-425.
29. Weissbluth M. Naps in children: 6 months-7 years. *Sleep*. 1995;18:82-87.
30. Randazzo AC, Muehlbach MJ, Schweitzer PK, Walsh JK. Cognitive function following acute sleep restriction in children ages 10-14. *Sleep*. 1998;21:861-868.
31. Gozal D, Wang M, Pope DW Jr. Objective sleepiness measures in pediatric obstructive sleep apnea.